A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine

被引：2
|
作者：
de Wet, Joseph J. [1 ,2 ]
Ban, Joann K. [3 ]
Verdier, Gustavo [4 ]
Ling, Juejing [5 ]
Eberg, Maria [5 ]
Bunko, Andrean [5 ]
McKimm, Michael [4 ,6 ]
机构：
[1] Spectrum Hlth, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Family Practice, Vancouver, BC, Canada
[3] GSK, Mississauga, ON, Canada
[4] ViiV Healthcare, Montreal, PQ, Canada
[5] IQVIA, Kirkland, PQ, Canada
[6] ViiV Healthcare, 75 Queen St,Suite 1400, Montreal, PQ H3C2N6, Canada
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2023年 / 62卷 / 02期
关键词：
D O I：
10.1016/j.ijantimicag.2023.106839
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Real-World Effectiveness and Tolerability of Dolutegravir and Lamivudine 2-Drug Regimen in People Living with HIV: Systematic Literature Review and Meta-Analysis
    Fraysse, Jeremy
    Priest, Julie
    Turner, Matthew
    Hill, Steffan
    Jones, Bryn
    Verdier, Gustavo
    Letang, Emilio
    INFECTIOUS DISEASES AND THERAPY, 2025, 14 (02) : 357 - 383
  • [32] Three-year outcomes for Dolutegravir (DTG) plus Lamivudine (3TC) in ARTnaive and pre-treated people living with HIV-1 (PLHIV) in Germany: Real-world data from the German URBAN cohort
    Noe, S.
    Scholten, S.
    Wyen, C.
    Sabranski, M.
    Postel, N.
    Degen, O.
    Beer, D.
    Ummard-Berger, K.
    Westermayer, B.
    Dymek, K. M.
    Scherzer, J.
    HIV MEDICINE, 2023, 24 : 137 - 139
  • [33] Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV
    Hidalgo-Tenorio, Carmen
    Vinuesa, David
    Garcia-Vallecillos, Coral
    Munoz-Medina, Leopoldo
    Sequera, Sergio
    Javier, Rosario
    Angel Lopez-Ruz, Miguel
    Sadyrbaeva-Dolgova, Svetlana
    Pasquau, Juan
    VIRUSES-BASEL, 2022, 14 (12):
  • [34] Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study
    Perfezou, Pascale
    Hall, Nolwenn
    Duthe, Jean-Charles
    Abdi, Basma
    Seang, Sophie
    Arvieux, Cedric
    Lamaury, Isabelle
    Menard, Amelie
    Marcelin, Anne-Genevieve
    Katlama, Christine
    Palich, Romain
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (08) : 1929 - 1933
  • [35] Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
    Schneider, Stefan
    Blick, Gary
    Burke, Christina
    Ward, Douglas
    Benson, Paul
    Felizarta, Franco
    Green, Dallas
    Donovan, Cynthia
    Harper, Gavin
    Merrill, Deanna
    Metzner, Aimee A.
    Mycock, Katie
    Wallis, Hannah
    Patarroyo, Jimena
    Brogan, Andrew P.
    Oglesby, Alan
    INFECTIOUS DISEASES AND THERAPY, 2024, 13 (04) : 891 - 906
  • [36] Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
    Stefan Schneider
    Gary Blick
    Christina Burke
    Douglas Ward
    Paul Benson
    Franco Felizarta
    Dallas Green
    Cynthia Donovan
    Gavin Harper
    Deanna Merrill
    Aimee A. Metzner
    Katie Mycock
    Hannah Wallis
    Jimena Patarroyo
    Andrew P. Brogan
    Alan Oglesby
    Infectious Diseases and Therapy, 2024, 13 : 891 - 906
  • [37] Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study
    Lombardi, Francesca
    Sanfilippo, Alessia
    Fabbiani, Massimiliano
    Borghetti, Alberto
    Ciccullo, Arturo
    Tamburrini, Enrica
    Di Giambenedetto, Simona
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (09) : 2315 - 2322
  • [38] One year of follow-up after switching to doravirine in treatment-experienced people living with HIV: a real-world cohort study
    Lanting, V.
    Oosterhof, P.
    Moha, D. Ait
    van Heerde, R.
    Kleene, M.
    Stalenhoef, J.
    de Regt, M.
    Vrouenraets, S.
    van den Berk, G.
    Brinkman, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 102 - 102
  • [39] Virological efficacy of dolutegravir plus darunavir in multi-drug-resistant HIV patients: a real-world cohort study with data from the PRESTIGIO registry
    Lagi, Filippo
    Bellomo, Michele
    Lolatto, Riccardo
    Ducci, Filippo
    Kiros, Seble Tekle
    Papaioannu, Rebecka
    Celemente, Tommaso
    Calza, Leonardo
    Feasi, Marcello
    Foca, Emanuele
    Giacomelli, Andrea
    Gulminetti, Roberto
    Menzaghi, Barbara
    Castagna, Antonella
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 127 - 128
  • [40] Comment on: Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study
    Giacomelli, Andrea
    Cossu, Maria Vittoria
    Moschese, Davide
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2023, 78 (12) : 3009 - 3010
12345